vs
Context Therapeutics Inc.（CNTX）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
Context Therapeutics Inc.的季度营收约是REZOLVE AI PLC的1.0倍（$1.2M vs $1.2M），REZOLVE AI PLC净利率更高（-1078.8% vs -1403.9%，领先325.1%）
Context Therapeutics Inc.是一家临床阶段生物制药公司，专注于开发激素驱动型癌症的创新靶向疗法，核心管线覆盖乳腺癌、卵巢癌等妇科恶性肿瘤候选药物，主要服务北美、欧洲地区的肿瘤患者与医疗提供方。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
CNTX vs RZLV — 直观对比
营收规模更大
CNTX
是对方的1.0倍
$1.2M
净利率更高
RZLV
高出325.1%
-1403.9%
损益表 — Q3 FY2024 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $1.2M |
| 净利润 | $-17.5M | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | -1503.7% | -808.4% |
| 净利率 | -1403.9% | -1078.8% |
| 营收同比 | 328.2% | — |
| 净利润同比 | -197.2% | — |
| 每股收益（稀释后） | $-0.22 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNTXRZLV
| Q2 25 | — | $1.2M | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | $840.1K | — | ||
| Q4 23 | $224.7K | — | ||
| Q3 23 | $290.4K | — | ||
| Q2 23 | $293.3K | — | ||
| Q1 23 | $355.5K | — | ||
| Q4 22 | $327.9K | — |
净利润CNTXRZLV
| Q2 25 | — | $-13.0M | ||
| Q3 24 | $-17.5M | — | ||
| Q2 24 | $-2.3M | — | ||
| Q4 23 | $-6.8M | — | ||
| Q3 23 | $-5.9M | — | ||
| Q2 23 | $-5.0M | — | ||
| Q1 23 | $-6.3M | — | ||
| Q4 22 | $-3.6M | — |
营业利润率CNTXRZLV
| Q2 25 | — | -808.4% | ||
| Q3 24 | -1503.7% | — | ||
| Q2 24 | -367.6% | — | ||
| Q4 23 | -3085.3% | — | ||
| Q3 23 | -2128.0% | — | ||
| Q2 23 | -1804.6% | — | ||
| Q1 23 | -1875.0% | — | ||
| Q4 22 | -1184.1% | — |
净利率CNTXRZLV
| Q2 25 | — | -1078.8% | ||
| Q3 24 | -1403.9% | — | ||
| Q2 24 | -268.3% | — | ||
| Q4 23 | -3012.6% | — | ||
| Q3 23 | -2022.7% | — | ||
| Q2 23 | -1708.8% | — | ||
| Q1 23 | -1774.3% | — | ||
| Q4 22 | -1084.8% | — |
每股收益（稀释后）CNTXRZLV
| Q2 25 | — | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q4 23 | $-0.42 | — | ||
| Q3 23 | $-0.37 | — | ||
| Q2 23 | $-0.31 | — | ||
| Q1 23 | $-0.40 | — | ||
| Q4 22 | $-0.22 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $83.9M | $-14.3M |
| 总资产 | $86.3M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CNTXRZLV
| Q2 25 | — | — | ||
| Q3 24 | $84.8M | — | ||
| Q2 24 | $101.5M | — | ||
| Q4 23 | $14.4M | — | ||
| Q3 23 | $21.7M | — | ||
| Q2 23 | $25.1M | — | ||
| Q1 23 | $29.8M | — | ||
| Q4 22 | $35.5M | — |
股东权益CNTXRZLV
| Q2 25 | — | $-14.3M | ||
| Q3 24 | $83.9M | — | ||
| Q2 24 | $101.1M | — | ||
| Q4 23 | $11.9M | — | ||
| Q3 23 | $18.4M | — | ||
| Q2 23 | $24.0M | — | ||
| Q1 23 | $28.7M | — | ||
| Q4 22 | $34.8M | — |
总资产CNTXRZLV
| Q2 25 | — | $80.1M | ||
| Q3 24 | $86.3M | — | ||
| Q2 24 | $102.7M | — | ||
| Q4 23 | $16.1M | — | ||
| Q3 23 | $23.0M | — | ||
| Q2 23 | $27.8M | — | ||
| Q1 23 | $32.0M | — | ||
| Q4 22 | $38.0M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.9M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | $-1.9M | — |
| 自由现金流率自由现金流/营收 | -156.0% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CNTXRZLV
| Q2 25 | — | $-4.9M | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | $-3.4M | — | ||
| Q4 23 | $-7.2M | — | ||
| Q3 23 | $-3.5M | — | ||
| Q2 23 | $-4.6M | — | ||
| Q1 23 | $-5.7M | — | ||
| Q4 22 | $-3.9M | — |
自由现金流CNTXRZLV
| Q2 25 | — | — | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
自由现金流率CNTXRZLV
| Q2 25 | — | — | ||
| Q3 24 | -156.0% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
资本支出强度CNTXRZLV
| Q2 25 | — | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.0% | — | ||
| Q1 23 | 0.0% | — | ||
| Q4 22 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
